(Q40047672)

16 September 2017

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer (English)

1 reference

16 September 2017

1 reference

Xiaozhong Qian

1

1 reference

16 September 2017

Gulshan Ara

2

1 reference

16 September 2017

Evan Mills

3

1 reference

16 September 2017

William J LaRochelle

4

1 reference

16 September 2017

Henri S Lichenstein

5

1 reference

16 September 2017

Michael Jeffers

6

1 reference

16 September 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

International Journal of Cancer

16 September 2017

1 reference

16 September 2017

122

1 reference

16 September 2017

1400-1410

1 reference

16 September 2017

6

1 reference

Anticancer activities of histone deacetylase inhibitors

16 September 2017

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

21 January 2018

1 reference

Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.

21 January 2018

1 reference

The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.

21 January 2018

1 reference

21 January 2018

The Hallmarks of Cancer

1 reference

Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.

21 January 2018

1 reference

The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer

21 January 2018

1 reference

Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells

21 January 2018

1 reference

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

21 January 2018

1 reference

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

21 January 2018

1 reference

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers

21 January 2018

1 reference

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

21 January 2018

1 reference

Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity

21 January 2018

1 reference

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation

21 January 2018

1 reference

Novel functions of TIMPs in cell signaling

21 January 2018

1 reference

Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization

21 January 2018

1 reference

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming

21 January 2018

1 reference

21 January 2018

1 reference

Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer

21 January 2018

1 reference

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer

21 January 2018

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer

21 January 2018

1 reference

Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.23243

1 reference

16 September 2017

1 reference